Skip to main content
OpenTrials
Completed

NCT Number: NCT03239717

The Metabolic Response to Reduced Branched-chain Amino Acids in Humans

Branched-chain amino acids (BCAAs) are essential nutrients that the body obtains from proteins found in food, especially meat, diary products, and legumes. Data from rodent studies suggest that reduction of dietary BCAAs will promote fat mass loss and improved control of blood glucose. The purpose of this study is to test if reduction of dietary BCAAs without reducing calorie intake will lead to similar metabolic benefits in humans. Here the investigators test the feasibility of reducing dietary BCAAs using BCAA-free meal replacement beverages for two months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Wisconsin-Madison School of Medicine and Public Health

Madison, Wisconsin, 53726, United States

About this study

This study, which will be completed over three months, involves replacing two meals a day with meal replacement beverages for two months, with a one month follow-up visit. These beverages will be made up by subjects using either a complete protein powder or BCAD2, a BCAA-free medical food. Participants will complete food diaries at baseline and at one month intervals during the study, and compliance will be assessed via food diaries, weekly telephone contact, and measuring returned food powder.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male between the age of 35 - 65
  • BMI between 28 - 35 (mildly obese/overweight)
  • Fasting glucose level of 101 - 125 mg/dL
  • Able and willing to give written informed consent
  • Stable weight (within 5 lbs. for at least 3 months)
  • Not taking (or willing to cease taking) over the counter vitamin/mineral supplements
  • Not planning to begin an exercise or diet program

Exclusion criteria

  • Female
  • Outside required age range of 35 - 65
  • BMI not within range of 28 - 35
  • Fasting glucose not within range of 101 - 125 mg/dL
  • Use of prescription medications for diabetes or weight-loss
  • Use of and unwillingness to discontinue over the counter supplements (e.g. cinnamon, chromium, protein powders) or weight loss beverage or meal plans (e.g. SlimFast or Jenny Craig).
  • Low baseline albumin or pre-albumin levels (below normal reference range)
  • Significant anemia (Hemoglobin < 11 g/dL)
  • Known bleeding disorder or platelet dysfunction
  • Already eating a low protein diet (less than 14% total caloric intake from protein), as calculated from food diaries provided by subjects
  • Participating in intensive exercise training program (high to moderate intensity exercise greater than 210 minutes per week) or planning to start new exercise program during study period.
  • Significant co-morbidities (including kidney disease, liver disease, GI disease, cardiovascular disease, respiratory disease, malnutrition, substance abuse, psychiatric disease, or a diagnosed eating disorder).
  • Planned smoking cessation or attempt at smoking cessation during study period
  • Inability to tolerate meal replacement beverages due to palatability
  • Recent weight loss (> 5 lbs within 3 months).
  • Bariatric surgery, gastric banding or liposuction
  • Current or past (within 1 year) use of illicit drugs
  • Claustrophobia

Treatment and study plan

Whey protein powder

Other

Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.

BCAD2

Other

Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.

Primary outcomes

  1. Reduction of BCAA intake

    Time frame: 3 months

    The principle outcome of this study is to determine if replacing 2/3rds of the subjects baseline protein intake with BCAA-free meal replacement beverages are a feasible method of selectively reducing BCAA consumption. Our principle outcome is to reduce BCAA intake by 50% or more in the Experimental Arm (BCAD2) of the study as compared to baseline intake.

Secondary outcomes

  1. Weight

    Time frame: 3 months

    Weight in kg

  2. Fat mass

    Time frame: 3 months

    Fat mass in kg

  3. BMI

    Time frame: 3 months

    Weight in kg and height in meters will be combined to report BMI in kg/m^2

  4. Resting metabolic rate

    Time frame: 3 months

    Resting metabolic rate in kcal/hour

  5. Fasting blood glucose

    Time frame: 3 months

    Fasting blood glucose in mg/dL

  6. Insulin

    Time frame: 3 months

    Insulin in ng/dL

  7. HbA1c

    Time frame: 3 months

    HbA1c in mmol/mol

  8. Glucose tolerance

    Time frame: 3 months

    Area under the curve in mg/dL/min

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Acronym: SOAR

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Aug 4, 2017
Registry last updated
Jul 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.